Daiichi Sankyo

Lungs
#Antibody drug conjugate (ADC) #AstraZeneca #Daiichi Sankyo #FDA #Lung cancer #Oncology

First TROP2-directed therapy approved in the US for lung cancer

Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).  It is approved in patients who have received prior EGFR-directed therapy and platinum-based chemotherapy.  The indication was… Read More

#News #Regulatory #Trending News

Cancer cells
#Antibody drug conjugate (ADC) #AstraZeneca #Breast cancer #Daiichi Sankyo #FDA #Oncology

FDA approved ADC improves breast cancer survival by 37%

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan-dlnk (Datroway) a Trop-2-directed antibody and topoisomerase inhibitor conjugate, as a treatment for breast cancer.  The decision was based on the results of the Phase III TROPION-Breast01 trial which showed a 37% reduction in the risk of… Read More

#News #Regulatory

Bispecific antibodies
#Bispecific Antibodies #Bispecific therapeutics #Daiichi Sankyo #Oncology #Partnership #Solid tumours

Partners invite proposals for multi-functional biologics research

Daiichi Sankyo and German research institute BioMed X have agreed a new partnership to advance the development of bi- and multi-specific biologics for treating solid tumours.  The new project, entitled ‘New Strategies for Targeting of Solid Tumours with Multi-Specific Biologics (MTT; Multi-Specific Targeting of Tumours)’, will be… Read More

#Business & Investment #News

Antibody drug conjugate
#Accelerated assessment #Antibody drug conjugate (ADC) #AstraZeneca #Daiichi Sankyo #FDA #Oncology #Solid tumours

First tumour agnostic HER2 directed ADC gets US approval

Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumours. Enhertu has been granted accelerated approval to treat patients who have received prior systemic treatment and… Read More

#News #Regulatory

#Association of the British Pharmaceutical Industry #Daiichi Sankyo #Prescription Medicines Code of Practice Authority (PMCPA) #Teva

Teva and Daiichi Sankyo found in breach of the UK ABPI Code

Both Teva and Daichi Sankyo have been found to be in breach of the Association of the British Pharmaceutical Industry (ABPI) Code of Practice by the Prescription Medicines Code of Practice Authority (PMCPA). Teva was ruled in breach of several clauses of the 2019 Code for… Read More

#News

Acute myeloid leukaemia
#Acute Myeloid Leukaemia #Blood cancer #Daiichi Sankyo #MHRA #Oncology

UK approves quizartinib for FLT3-ITD-positive AML

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Daiichi Sankyo’s quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults with acute myeloid leukaemia (AML). Each year in the UK around 3,100 people are diagnosed with AML. Julian… Read More

#News #Regulatory

FDA
#Acute Myeloid Leukaemia #Daiichi Sankyo #FDA #Haematology #Leukaemia

FDA approves quizartinib for acute myeloid leukaemia

The US Food and Drug Administration (FDA) has approved Daiichi Sankyo’s quizartinib (Vanflyta) for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3 internal tandem duplication (ITD)-positive. It is approved with standard cytarabine and anthracycline induction and cytarabine consolidation, and… Read More

#News #Regulatory

#ABPI #AstraZeneca #Daiichi Sankyo #LEO Pharma #Prescription Medicines Code of Practice Authority (PMCPA) #Regulatory

Pharma watchdog calls out Leo, AZ and Daiichi Sankyo for misleading ads 

The Prescription Medicines Code of Practice Authority (PMCPA), a self-regulatory body which administers the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry, have opened cases against Leo Pharma, AstraZeneca and Daiichi Sankyo for bringing discredit upon, and reducing confidence in, the pharmaceutical industry. Read More

#News #Regulatory

#Covid-19 #Daiichi Sankyo #Drug discovery #Fujifilm Toyama Chemical #Japan #Takeda

Japanese drug development: Where is the innovation? 

Lu Rahman looks at how opportunities are growing in Japanese drug development and where innovation is coming from. Japan is a fascinating drug discovery and development market. A strong pharmaceutical sector (some reports place it second globally behind the US), an ageing population and a tranche of expertise, put the… Read More

#Editor's Choice #Exclusive Content #Market Reports